AI Drug Discovery Company XtalPi Secures $15M Series B Funding Led by Sequoia China, with Participation from Google and Tencent

 1Month24Recently, VCBeat learned that,AIPharmaceutical R&D company XtalPi (XtalPi) announced that it has recently completed approximately1500of $10,000Bround of financing, led by Sequoia Capital China (hereinafter referred to as “Sequoia China”), with Google participating as a co-investor,ATencent, a participating investor in this round, continued to increase its investment. XtalPi’s total fundraising exceeded2000$10,000, becomingAIOne of the companies with the highest total financing amount in the pharmaceutical R&D sector.

Founded on the MIT campus in 2014, XtalPi is committed to computation-driven innovation, striving to build next-generation Intelligent Digital Drug Discovery and Development (ID4) technologies to address challenges related to efficiency and success rates in preclinical drug research.

The company integrates quantum physics, artificial intelligence, and ultra-large-scale cloud computing to achieve breakthrough rapid and accurate prediction of key properties of small-molecule drugs, possessing multiple industry-leading technologies in fields such as drug design and solid-phase drug screening.

Existing investors of XtalPi also includeZhenFund & FreeS Fund. The company has established stable and in-depth collaborations with multiple world-leading pharmaceutical companies and new drug research institutions, achieving several milestone breakthroughs.

AtomPai aims to provide a platform that enables users with data analysis and intelligent analytics needs to rapidly build data analysis models, perform predictions, generate analytical reports, and visualize report results, with a focus on simplicity, ease of use, and model sharing.

Through AtomPai, users can flexibly customize AI and statistical models tailored to their research needs, or directly utilize mature models shared by other users on the platform. This enables rapid completion of data analysis tasks without writing a single line of code, allowing users to download analysis results along with related reports and charts.

No coding required. AtomPai helps users gain deeper insights into data with just a few clicks, enabling the rapid creation of concise, visually appealing, and focused analytical reports. The platform currently offers dozens of analytical models, ranging from basic logistic regression and principal component analysis (PCA) to deep learning models specifically designed for the scientific research and pharmaceutical industries.

Wen Shuhao, Co-founder and Chairman of XtalPi, stated, “XtalPi has always firmly believed in the power of algorithms to deliver faster and more efficient drug discovery technologies, thereby promoting the digitalization and intelligent transformation of the pharmaceutical industry. We hope our technology can serve as an acceleration engine for innovative drug R&D both in China and globally, overcoming the long-standing challenges and limitations inherent in traditional development models, and enabling more high-quality, effective medicines to reach patients more quickly. Receiving support from top-tier investors in the fields of artificial intelligence and computer science, such as Sequoia China, Google, and Tencent, is a significant affirmation of our technology, and we look forward to further collaboration with them in the future.”

Neil Shen, Global Executive Partner at Sequoia Capital, stated: “XtalPi’s technological innovations offer unique solutions to the pain points and bottlenecks in drug R&D that stem from a heavy reliance on experimental trial and error. Sequoia China’s investment in XtalPi reflects our confidence in the prospects of AI-driven transformation within the pharmaceutical industry. With its strengths in technology, team, and business model, the company is well-positioned to become a leader in this field. We look forward to helping XtalPi realize its value and grow into a successful and influential enterprise.”

Lin Yifan of Google’s Corporate Investment and Development Division stated, “XtalPi’s AI-powered R&D platform has the potential to become the new standard in the drug discovery industry. Its intelligent drug development technology enhances the capabilities and efficiency of new drug research and development while reducing costs. We are honored to collaborate with this highly capable team and look forward to their future growth.”

“After securing Series A funding from Tencent, XtalPi has developed rapidly, with its innovations in AI-driven drug discovery gaining recognition from world-renowned pharmaceutical companies,” said Li Zhaohui, Partner at Tencent Investment. “Tencent’s additional investment in this round reflects our confidence in the innovation capabilities and execution strength of the XtalPi team, as well as our optimism about the future development of AI-driven drug discovery.”

Following the completion of this round of financing, XtalPi will fully leverage its existing technological advantages to continue advancing collaborative R&D projects with international pharmaceutical companies and research institutions, while expanding into upstream and downstream segments of the drug development value chain. On one hand, XtalPi will establish a crystallization laboratory guided by high-precision predictions, empowering drug researchers with unprecedented capabilities in solid-state drug design, thereby further enhancing R&D efficiency and project success rates. On the other hand, it will develop new algorithmic applications by leveraging the vast amount of high-precision computational data accumulated on its platform, providing more comprehensive solutions for new drug development.

For more information about XtalPi, please click “Leveraging AI and quantitative computing for new drug development, XtalPi is the first mover in China.》